Organization
Westlake Therapeutics Co., Ltd.
1 abstract
Abstract
WTX212, an erythrocyte-anti-PD1 antibody conjugate, to demonstrate anti-tumor activities in tumor models and patients with cancer with acquired resistance to immunotherapy.Org: Westlake University, Westlake Institute for Advanced Study, Westlake Therapeutics Co., Ltd.,